BG-75202 features among several projects starting first-in-human trials.
ApexOnco Front Page
Recent articles
There will soon be three PD-(L)1 x VEGF projects in pivotal lung and colorectal cancer trials.
Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.
US approval gives Pfizer the first and second-line settings.
But, like Merck two weeks ago, GSK has failed to hit overall survival.
Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
Data deteriorate, leaving cash-strapped Affimed relying on a post-hoc analysis and higher dosing.
